Bone mets and Afinitor

The combination of Afinitor (everolimus) plus Aromasin (exemestane) halved the rate of further bone metastases compared with exemestane alone in postmenopausal women with advanced breast cancer during the first 12 weeks of therapy. (BOLERO-2 study presented at the 8th European Breast Cancer Conference in Vienna, Austria.)